Nurix Therapeutics (NRIX) Shares Outstanding (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $103.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 35.68% year-over-year to $103.7 million; the TTM figure through May 2026 stood at $103.7 million (up 35.68% YoY), while the FY2025 annual figure was $101.8 million, up 34.19% from the prior year.
• Shares Outstanding (Entity) steadied at $103.7 million in Q2 2026 per NRIX's latest filing, from $103.4 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $103.7 million in Q2 2026 and bottomed at $44.9 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $65.1 million across 5 years, with a median of $56.7 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 1.43% — and 2024, when it soared 55.73%.
• Nurix Therapeutics' Shares Outstanding (Entity) stood at $47.2 million in 2022, then climbed by 3.28% to $48.7 million in 2023, then surged by 55.73% to $75.9 million in 2024, then surged by 34.19% to $101.8 million in 2025, then increased by 1.86% to $103.7 million in 2026.
• Business Quant data shows NRIX's Shares Outstanding (Entity) at $103.7 million in Q2 2026, $103.4 million in Q1 2026, and $101.8 million in Q4 2025.